Term ends Sep 6, 2033 · Medium confidence
20-year base term ends Sep 6, 2033
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 9,340,612, US 9,382,317, US 9,782,479), so the cap could be lower.
Sep 6, 2013
Sep 6, 2033
Sep 22, 2020
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 3 maintenance fees is paid so far. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 6, 2013, when application 14/020,733, the earliest non-provisional in its chain, was filed (this one was filed Jul 18, 2017) | Sep 6, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,340,611, US 9,340,612, US 9,382,317, US 9,682,145, US 9,724,414, US 9,731,008, US 9,731,009, US 9,737,600, US 9,757,454, US 9,770,507, US 9,782,479, US 9,808,525) | resolves to Sep 6, 2033, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Sep 6, 2033 | Medium confidence |
This family
| Application 14/020,733 | Abandoned not computed | not computed |
| US 9,340,611 | Lapsed on the fee record May 2024 | May 2024 |
| US 9,340,612 | Lapsed on the fee record May 2024 | May 2024 |
| US 9,782,479 | Lapsed on the fee record Oct 2025 | Oct 2025 |
| US 9,346,880 | Lapsed on the fee record May 2024 | May 2024 |
| US 9,382,317 | Lapsed on the fee record Jul 2024 | Jul 2024 |
| US 9,724,414 | Lapsed on the fee record Aug 2025 | Aug 2025 |
| US 9,808,525 | Lapsed on the fee record Nov 2025 | Nov 2025 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 28, 2018 Reel 47007, frame 8 | Manning, Mark; Payne, Robert W. | Coherus Biosciences, Inc. | Assignment of Assignor's Interest |
| Jan 7, 2019 Reel 48021, frame 975 | Coherus Biosciences, Inc.; Coherus Intermediate Corp.; Intekrin Therapeutics Inc. | HCR Collateral Management, LLC, as Administrative Agent | Security Interest |
| Jan 21, 2020 Reel 51565, frame 249 | Manning, Mark; Payne, Robert W. | Coherus Biosciences, Inc. | Assignment of Assignor's Interest |
| Jan 11, 2022 Reel 58692, frame 665 | HCR Collateral Management, LLC | Coherus Biosciences, Inc.; Coherus Intermediate Corp.; Intekrin Therapeutics Inc. | Release of Notice of Grant of Security Interest in Patents at Reel/Frame No. 048021/0975 |
| Jan 11, 2022 reel/frame not recorded | HCR Collateral Management, LLC | Coherus Biosciences, Inc. | Release of Notice of Grant of Security Interest in Patents at Reel/Frame No. 048021/0975 |
| Jan 11, 2022 reel/frame not recorded | HCR Collateral Management, LLC | Coherus Intermediate Corp. | Release of Notice of Grant of Security Interest in Patents at Reel/Frame No. 048021/0975 |
| Jan 11, 2022 reel/frame not recorded | HCR Collateral Management, LLC | Intekrin Therapeutics Inc. | Release of Notice of Grant of Security Interest in Patents at Reel/Frame No. 048021/0975 |
| Mar 18, 2022 Reel 59436, frame 55 | Coherus Biosciences, Inc.; Coherus Intermediate Corp.; Intekrin Therapeutics Inc. | Biopharma Credit PLC | Security Interest |
| May 8, 2024 Reel 67348, frame 160 | Coherus Biosciences, Inc.; Coherus Intermediate Corp.; Intekrin Therapeutics Inc.; Surface Oncology, LLC; Coherus Oncology Supportive Care LLC | Ankura Trust Company, LLC | Security Interest |
| May 9, 2024 Reel 67378, frame 256 | Biopharma Credit PLC, as Collateral Agent | Coherus Biosciences, Inc.; Coherus Intermediate Corp.; Intekrin Therapeutics Inc. | Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 59436/0055 |
| May 9, 2024 reel/frame not recorded | Biopharma Credit PLC, as Collateral Agent | Coherus Biosciences, Inc. | Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 59436/0055 |
| May 9, 2024 reel/frame not recorded | Biopharma Credit PLC, as Collateral Agent | Coherus Intermediate Corp. | Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 59436/0055 |
| May 9, 2024 reel/frame not recorded | Biopharma Credit PLC, as Collateral Agent | Intekrin Therapeutics Inc. | Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 59436/0055 |
| Oct 31, 2024 Reel 69084, frame 884 | Coherus Biosciences, Inc. | Hong Kong King-Friend Industrial Company Ltd. | Assignment of Assignor's Interest |
| Aug 14, 2026 Reel 76509, frame 590 | Ankura Trust Company, LLC, as Collateral Agent | Coherus Oncology, Inc. (F/K/A Coherus Biosciences, Inc.); Coherus Intermediate Corp.; Intekrin Therapeutics Inc.; Surface Oncology, LLC; Coherus Oncology Supportive Care LLC | Release of Security Interest in Intellectual Property at Reel/Frame No. 67348/0160 |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 9,340,611, US 9,340,612, US 9,382,317, US 9,682,145, US 9,724,414, US 9,731,008, US 9,731,009, US 9,737,600, US 9,757,454, US 9,770,507, US 9,782,479, US 9,808,525, ends no earlier than this term, so it caps nothing.